Methods for identification, diagnosis, and treatment of breast cancer
The invention provides methods of identifying premalignant and malignant breast cancer, determining lymph node involvement in patients diagnosed with premalignant and malignant breast cancer growths, and methods of treating premalignant and malignant breast cancer. The diagnostic and methods comprise intraductal administration of a targeting molecule either alone acting as an identifying agent, or coupled to an identifying agent; the therapeutic methods comprise intraductal administration of a targeting molecule coupled to a therapeutic agent or administration of a targeting molecule having therapeutic activity in and of itself.
1 - 16 . (canceled)
17 . A method of treating premalignant or malignant breast cancer, said method comprising: providing a targeting molecule coupled to a therapeutic agent; and delivering the coupled compound through a preselected individual breast duct in an amount sufficient to inhibit proliferation of the cancerous cells.
18 . A method as in claim 17 , wherein delivering comprises cannulation or catheterization of the breast duct.
19 . A method as in claim 17 , wherein the coupled compound is delivered to more than one duct on a breast.
20 . A method as in claim 17 , wherein the targeting agent comprises an agent selected from the group consisting of a protein, a polypeptide, a peptide, an antibody, an antibody fragment, a ligand, a receptor, a drug, a chemical, a lipid, a liposome, a small molecule, and a nucleic acid.
21 . A method as in claim 17 , wherein the therapeutic agent is selected from the group consisting of a cytotoxic agent, a cytolytic agent, a growth inhibiting agent, an antagonist, an agonist, and a drug or agent containing liposome.
22 . A method as in claim 17 , wherein the therapeutic agent comprises an agent with therapeutic activity against cancerous or precancerous cells that can be coupled to a targeting agent.
23 . A method of treating a premalignant or malignant breast cancer, said method comprising: providing a targeting molecule itself having therapeutic activity; and delivering the targeting molecule through a preselected individual breast duct in an amount sufficient to inhibit proliferation of the cancerous cells.
24 . A method as in claim 23 , wherein delivering comprises cannulation or catheterization of the breast duct.
25 . A method as in claim 23 , wherein the targeting molecule is delivered to more than one duct on a breast.
26 . A method as in claim 23 , wherein the targeting molecule comprises an agent selected from the group consisting of a protein, a polypeptide, a peptide, an antibody, an antibody fragment, a ligand, a receptor, a drug, a chemical, a lipid, a liposome, a small molecule, and a nucleic acid.
27 . A method as in claim 23 , wherein the therapeutic activity is selected from the group consisting of a cytotoxicity, a cytolytic activity, growth inhibition, antagonism, an agonism, and immunotoxicity.
28 . A method as in claim 23 , wherein the therapeutic activity is effective against cancerous or precancerous cells.
29 . A method as in claim 17 or 23 , wherein the premalignant or malignant breast cancer comprises cells having a stage selected from the group consisting of hyperplasia, atypical hyperplasia, low-grade ductal carcinoma in situ, high-grade ductal carcinoma in situ, and invasive carcinoma.
30 - 32 . (canceled)